低分子肝素与普通肝素辅助治疗老年重症肺炎的效果对比分析

Low molecular weight heparin versus heparin in treatment of severe pneumonia in the elderly

目的比较分析低分子肝素与普通肝素辅助治疗老年重症肺炎的效果。方法选取本院2013年1月至2015年1月收治的老年重症肺炎患者100例作为观察对象，根据患者具体用药的不同将其分为低分子肝素组（观察组）和普通肝素组（对照组），分析比较治疗后两组临床效果、相关检测指标等。结果观察组治疗总有效率89．29％，明显高于对照组的79．55％，差异具有统计学意义（P〈0．05）。治疗后，观察组体温[（36．46±0．67）℃]、WBC[（8．67±3．88）×109／L]、RR[（16．45±2．73）次／min]、HR[（76．79±4．95）次／min]、Sa02[（96．68±4．49）％]、Pa02／Fi02[（222．47±35．89）]mmHg（1mmHg=0．133kPa）各项检测指标均好于对照组。结论老年重症肺炎患者在常规治疗基础上加用低分子肝素在改善肺部氧合、抗凝等方面具有积极意义。

Objective To analyze the effect of low molecular weight heparin versus common heparin in the treatment of elderly patients with severe pneumonia. Methods 100 elderly patients with severe pneumonia treated at our hospital from January, 2013 to January, 2015 were selected as observation objects and were divided into an observation group, treated with low molecular weight heparin, and a control group, treated with common heparin, according to different treatment drugs. The clinical effect and relevant anthropometric indicators were analyzed and compared between these two group after the treatment. Results The total efficacy was 89.29% in the observation group and was 79.55% in the control group, with a statistical difference （P〈0.05）. After the treatment, the body temperature was （36.46 ± 0.67） ℃, WBC （8.67 ± 3.88） x109/L, RR 06.45 ± 2.73） times/min, HR （76.79 ± 4.95） times/min, SaO2 （96.68 ± 4.49）%, and Pa0E/Fi02 （222.47 ±35.89） mmHg in the observation group, which were better than those in the control group. Conclusion Low molecular weight heparin in the treatment of elderly patients with severe pneumonia is of positive significance in improving pulmonary oxygenation, anticoagulation, and so on.